<DOC>
	<DOCNO>NCT00277862</DOCNO>
	<brief_summary>Genotype 4 least-studied hepatitis C virus genotype consider difficult treat genotype due disappointing response chronic hepatitis C genotype 4 conventional interferon monotherapy . Recent report show pegylated interferon ribavirin combination therapy markedly increase SVR rate 55-70 % . The duration treatment accurately define . The main objective ass duration pegylated interferon ribavirin therapy chronic hepatitis genotype 4 ass clinical utility rapid early virologic response determine optimal duration peg interferon ribavirin therapy chronic hepatitis C .</brief_summary>
	<brief_title>Pegylated Interferon Ribavirin Therapy Chronic Hepatitis Genotype 4</brief_title>
	<detailed_description>Hepatitis C virus ( HCV ) genotype 4 frequent cause chronic hepatitis C Middle East , North Africa sub-Saharan Africa . In country like Egypt , 73 90 % case chronic hepatitis C cause genotype 4 . Recently , epidemiological report show spread HCV-4 infection Western country France , Italy , Greece , Spain United States particularly among intravenous drug user . Genotype 4 least-studied hepatitis C virus genotype consider difficult treat genotype due disappointing response chronic hepatitis C genotype 4 conventional interferon monotherapy . Recent report show pegylated interferon ribavirin combination therapy markedly increase SVR rate 55-70 % . We previously show , treatment patient chronic HVCG4with PEG-IFN α-2b plus ribavirin 36 48 week effective ( SVR 66 % 69 % , respectively ) 24 week . It show previous study chronic hepatitis C genotype 1 individual achieve early virologic high chance achieve sustain virologic response . Peg interferon ribavirin therapy associate adverse event expensive ; therefore , careful determination optimal treatment duration crucial spare patient unnecessary prolong therapy enhances cost-effectiveness therapy . Therefore main objective randomize , multicenter trial ass clinical utility rapid early virologic response determine optimal duration peg interferon ribavirin therapy chronic hepatitis C .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult male female , 18 50 year age ; document chronic hepatitis C accord follow criterion : elevate serum alanine aminotransferase ( ALT ) upper limit normal ( 40 U/l ) two occasion precede six month ; antiHCV positive antibody status assess second generation enzyme link immunosorbent assay ( Roche Diagnostics , Branchburg , New Jersey , USA ) ; positive polymerase chain reaction HCV RNA ( Cobas Amplicor HCV Monitor v2.0 ; low limit quantitation 50 IU/mL ) ; genotype 4 ; criterion chronic hepatitis C liver biopsy perform within precede year sign cirrhosis bridge fibrosis pretreatment liver biopsy . Previous IFNalpha therapy ; liver diseases hepatitis A , hepatitis B , schistosomiasis , autoimmune hepatitis , alcoholic liver disease , drug induce hepatitis , decompensated liver disease ; coinfection schistosomiasis human immunodeficiency virus ; neutro¬penia ( ,1 500/mm3 ) ; thrombocytopenia ( ,90 000/mm3 ) ; creatinine concentration .1.5 time upper limit normal ; serum fetoprotein concentration .25 ng/ml ; organ transplant ; neoplastic disease ; severe cardiac pulmonary disease ; unstable thyroid dysfunction ; psychiatric disorder ; current pregnancy breast feeding ; therapy immunomodulatory agent within last six month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>chronic hepatitis C ;</keyword>
	<keyword>peg-interferon alfa-2b ;</keyword>
	<keyword>ribavirin ,</keyword>
	<keyword>rapid virologic response ,</keyword>
	<keyword>sustained virological response</keyword>
</DOC>